01 Rise in Point-of-Care Testing (POCT) for Zika Virus The rise in point-of-care testing (POCT) for Zika virus is driven by the urgent need for rapid and accessible diagnostics, particularly in regions with limited laboratory infrastructure. Portable POCT devices offer on-site testing, which allows for faster identification of Zika infections and more efficient containment measures during outbreaks. This accessibility is crucial for rural and remote areas, where traditional laboratory access is limited, enabling healthcare providers to diagnose and respond to cases swiftly. For instance, in August 2023, a new POCT system was deployed in regions of Central America prone to Zika outbreaks, aiming to provide immediate results and help curb virus spread through early detection. These advancements in POCT not only improve the speed and accuracy of diagnoses but also bolster public health efforts by facilitating real-time response during outbreaks, ultimately enhancing overall Zika virus control and management.
02 Expansion of Multiplex Diagnostic Panels The demand for multiplex diagnostic panels, which detect multiple pathogens simultaneously, is rising in regions where Zika, dengue, and chikungunya viruses co-circulate. These panels streamline the diagnostic process by testing for several infections at once, improving efficiency and helping clinicians quickly identify the specific virus, even in cases with overlapping symptoms.This comprehensive approach is particularly beneficial in tropical and subtropical regions prone to multiple mosquito-borne viruses, enhancing the accuracy and speed of diagnosis in such high-risk areas. For instance, in September 2023, a new multiplex panel was launched in Southeast Asia, integrating Zika, dengue, and chikungunya testing to address the frequent outbreaks in the region. By reducing the need for multiple tests, these panels not only optimize laboratory resources but also enable quicker public health responses, supporting more effective disease monitoring and outbreak control.
June 2026 – Diagnostic Companies Continue Expansion of Molecular and Serological Zika Testing CapabilitiesLeading diagnostic companies continued advancing molecular testing, serological assays, and multiplex infectious disease testing platforms to support detection of Zika virus infections. Companies including Abbott, Roche, DiaSorin, Bio-Rad Laboratories, and Siemens Healthineers remain active in infectious disease diagnostics, including technologies applicable to Zika detection workflows.
April 2026 – Increased Focus on Rapid and Point-of-Care Zika Detection TechnologiesResearch institutions and diagnostic developers continued working on rapid Zika testing platforms designed to reduce dependence on centralized laboratories. Emerging approaches include portable molecular diagnostics, isothermal amplification methods, and simplified testing formats for outbreak monitoring and resource-limited regions.
February 2026 – Public Health Surveillance Programs Strengthen Zika Diagnostic PreparednessPublic health organizations continued improving mosquito-borne disease surveillance programs, including laboratory testing capacity for Zika virus differentiation from other arboviruses such as dengue and chikungunya. Enhanced surveillance supports outbreak response and prenatal diagnostic needs.
September 2025 – Advanced Molecular Diagnostic Platforms Support Arbovirus Testing ExpansionDiagnostic technology providers expanded the use of PCR-based and automated molecular platforms for infectious disease testing. These platforms support high-sensitivity detection workflows that are applicable for Zika virus confirmation in clinical laboratories.